Kowa Research Institute, Inc. is responsible for the clinical development of Kowa Company’s new drugs in the United States. The company is a division of Kowa Co., Ltd. headquartered in Nagoya, Japan. Kowa Research Institute was established in 1997 in California, began operations in the RTP area of North Carolina in 2003, and expanded to Boston, Massachusetts in 2018 with the establishment of Kowa Pharma Development Co.
Kowa Pharma Development (Kowa Research Institute’s branch in Boston) is the strategic headquarters of Kowa Co., Ltd.’s global clinical development activities.
Kowa Co., Ltd. is one of the largest privately held companies in Japan. Kowa manufactures pharmaceuticals, optical and electro-optical goods. It is also a world-wide trading organization handling chemicals, textiles and garments, machinery, fashion accessories and sporting goods.
For more information on the Kowa Group, please click below:
Affiliate Offices in the US:
Kowa Science Institute: https://cics.bwh.harvard.edu/
The Center for Interdisciplinary Cardiovascular Sciences (CICS) was established in 2009 by a collaboration agreement between the Brigham and Women’s Hospital (Boston, MA) and Kowa Company, Ltd. (Tokyo, Japan).
The goals of CICS are to promote better understanding of the mechanisms of cardiovascular inflammation and cardiometabolic disorders and to enhance further advancement in cardiovascular prevention and therapy through a translational research program that consists of investigators from academia and industry with multidisciplinary backgrounds acting in concert in a shared space.
Kowa Pharmacueticals America: https://www.kowapharma.com/
Kowa Pharmaceuticals America, Inc., headquartered in Montgomery, Alabama, is focused primarily in the area of cardiometabolic diseases. Established in 2008, Kowa Pharmaceuticals America, Inc. focuses its efforts on the successful commercialization of its current and near-term portfolio of pharmaceutical products and business development activities.